Silence Therapeutics’ (SLN) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Silence Therapeutics (NASDAQ:SLN) in a report issued on Friday, Benzinga reports. The firm currently has a $75.00 price target on the stock.

Separately, BMO Capital Markets initiated coverage on Silence Therapeutics in a research report on Wednesday, January 31st. They issued an outperform rating and a $67.00 target price for the company.

Silence Therapeutics Stock Up 5.1 %

Shares of SLN traded up $1.17 during mid-day trading on Friday, reaching $24.01. The company’s stock had a trading volume of 123,372 shares, compared to its average volume of 271,954. Silence Therapeutics has a 12-month low of $4.55 and a 12-month high of $27.72. The stock has a market cap of $718.57 million, a PE ratio of -16.81 and a beta of 1.45. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.56 and a quick ratio of 4.86. The company’s 50 day moving average is $21.83 and its 200 day moving average is $14.98.

Institutional Trading of Silence Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. Lombard Odier Asset Management USA Corp lifted its holdings in shares of Silence Therapeutics by 4.1% in the 2nd quarter. Lombard Odier Asset Management USA Corp now owns 4,120,416 shares of the company’s stock valued at $18,668,000 after buying an additional 161,315 shares during the period. Lombard Odier Asset Management Europe Ltd lifted its holdings in shares of Silence Therapeutics by 3.7% in the 2nd quarter. Lombard Odier Asset Management Europe Ltd now owns 3,415,360 shares of the company’s stock valued at $18,784,000 after buying an additional 121,955 shares during the period. Artal Group S.A. lifted its holdings in shares of Silence Therapeutics by 236.6% in the 2nd quarter. Artal Group S.A. now owns 1,700,000 shares of the company’s stock valued at $9,350,000 after buying an additional 1,194,926 shares during the period. Goldman Sachs Group Inc. lifted its holdings in shares of Silence Therapeutics by 27.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 965,815 shares of the company’s stock valued at $18,350,000 after buying an additional 205,815 shares during the period. Finally, Vivo Capital LLC acquired a new stake in shares of Silence Therapeutics in the 4th quarter valued at approximately $8,862,000. 64.27% of the stock is owned by institutional investors and hedge funds.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's mRNAi GOLD GalNAc Oligonucleotide Discovery platform that is used to target specific disease-associated genes in the liver.